Obesity: A Multi Perspective of Physiology and Neurobiology Energy Regulation

Anna Meiliana, Nurrani Mustika Dewi, Andi Wijaya


BACKGROUND: World Health Organization has reported four million people die every year due to obesity comorbidity, and the prevalence of obesity is keep increasing, especially after COVID-19. Obesity has been defined as a chronic disease involving adipose tissue dysfunction which leads to metabolic diseases and psychosocial consequences. The review article will highlight some recent researches regarding the new conceptual framework that integrates both metabolic drives, as well as to summarize the numerous discussions about the current understanding of hypothalamic control of food intake and energy homeostasis.

CONTENT: Obesity apparently is not simply regulated only by food and exercise. Hypothalamus takes part in controlling energy intake and expenditure via appetite regulation. Hedonic control in cortical and subcortical brain areas process cognitive, reward, information, and executive function. Managing metabolic adaptation, browning the white adipose tissue, and preserving lean mass can be another strategy to safely manage obesity.

SUMMARY: Obesity need to be managed in a multimodal strategy including neurophysiology and physiology approach, together with environment support. Thus, a weight regain can be prevented. Commitment from both scientific and regulation point of view can shed a light to eradicate obesity.

KEYWORDS: adipocyte, appetite, nutrition, obesity, physical activity, reward, satiety

Full Text:



Schwartz MW, Seeley RJ, Zeltser LM, Drewnowski A, Ravussin E, Redman LM, et al. Obesity pathogenesis: An endocrine society scientific statement. Endocr Rev. 2017; 38(4): 267–96, CrossRef.

Blackburn G. Effect of degree of weight loss on health benefits. Obes Res. 1995; 3(Suppl 2): 211s–6s, CrossRef.

Kraschnewski JL, Boan J, Esposito J, Sherwood NE, Lehman EB, Kephart DK, et al. Long-term weight loss maintenance in the United States. Int J Obes. 2010; 34(11): 1644–54, CrossRef.

Bray GA, Kim KK, Wilding JPH, World Obesity Federation. Obesity: A chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obes Rev. 2017; 18(7): 715–23, CrossRef.

Martins C, Dutton GR, Hunter GR, Gower BA. Revisiting the Compensatory Theory as an explanatory model for relapse in obesity management. Am J Clin Nutr. 2020; 112(5): 1170–9, CrossRef.

Willoughby D, Hewlings S, Kalman D. Body composition changes in weight loss: Strategies and supplementation for maintaining lean body mass, a brief review. Nutrients. 2018; 10(12): 1876, CrossRef.

Ida S, Kaneko R, Imataka K, Okubo K, Shirakura Y, Azuma K, et al. Effects of antidiabetic drugs on muscle mass in type 2 diabetes mellitus. Curr Diabetes Rev. 2021; 17(3): 293–303, CrossRef.

Bosy-Westphal A, Kossel E, Goele K, Later W, Hitze B, Settler U, et al. Contribution of individual organ mass loss to weight loss-associated decline in resting energy expenditure. Am J Clin Nutr. 2009; 90(4): 993–1001, CrossRef.

Berthoud HR. Metabolic and hedonic drives in the neural control of appetite: Who is the boss? Curr Opin Neurobiol. 2011; 21(6): 888– 96, CrossRef.

Berthoud HR. Mind versus metabolism in the control of food intake and energy balance. Physiol Behav. 2004; 81(5): 781–93, CrossRef.

CDC Centers for Disease Control and Prevention [Internet]. Defining Adult Overweight and Obesity [updated 2022 Jun 3; cited 2023 Apr 5]. Available from: https://www.cdc.gov/.

Piaggi P. Metabolic determinants of weight gain in humans. Obesity. 2019; 27(5): 691–9, CrossRef.

Sumithran P, Prendergast LA, Delbridge E, Purcell K, Shulkes A, Kriketos A, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011; 365(17): 1597–604, CrossRef.

Iepsen EW, Lundgren J, Holst JJ, Madsbad S, Torekov SS. Successful weight loss maintenance includes long-term increased meal responses of GLP-1 and PYY3-36. Eur J Endocrinol. 2016; 174(6): 775–84, CrossRef.

Nymo S, Coutinho SR, Jørgensen J, Rehfeld JF, Truby H, Kulseng B, et al. Timeline of changes in appetite during weight loss with a ketogenic diet. Int J Obes. 2017; 41(8): 1224–31, CrossRef.

Nymo S, Coutinho S, Eknes P, Vestbostad I, Rehfeld J, Truby H, et al. Investigation of the long-term sustainability of changes in appetite after weight loss. Int J Obes. 2018; 42(8): 1489–99, CrossRef.

Coutinho SR, Rehfeld JF, Holst JJ, Kulseng B, Martins C. Impact of weight loss achieved through a multidisciplinary intervention on appetite in patients with severe obesity. Am J Physiol Endocrinol Metab. 2018; 315(1): E91–8, CrossRef.

Coutinho SR, With E, Rehfeld JF, Kulseng B, Truby H, Martins C. The impact of rate of weight loss on body composition and compensatory mechanisms during weight reduction: A randomized control trial. Clin Nutr Edinb Scotl. 2018; 37(4): 1154–62, CrossRef.

Coutinho SR, Halset EH, Gåsbakk S, Rehfeld JF, Kulseng B, Truby H, et al. Compensatory mechanisms activated with intermittent energy restriction: A randomized control trial. Clin Nutr Edinb Scotl. 2018; 37(3): 815–23, CrossRef.

Meyer-Gerspach AC, Wölnerhanssen B, Beglinger B, Nessenius F, Napitupulu M, Schulte FH, et al. Gastric and intestinal satiation in obese and normal weight healthy people. Physiol Behav. 2014; 129: 265–71, CrossRef.

Locke AE, Kahali B, Berndt SI, Justice AE, Pers TH, Day FR, et al. Genetic studies of body mass index yield new insights for obesity biology. Nature. 2015; 518(7538): 197–206, CrossRef.

Berthoud HR. The caudal brainstem and the control of food intake and energy balance. In: Stricker EM, Woods SC, editors. Neurobiology of Food and Fluid Intake. New York: Kluwer Academic/Plenum Publishers; 2004. p.195–240, CrossRef.

Kaplan JM, Seeley RJ, Grill HJ. Daily caloric intake in intact and chronic decerebrate rats. Behav Neurosci. 1993; 107(5): 876–81, CrossRef.

Smith GP. The direct and indirect controls of meal size. Neurosci Biobehav Rev. 1996; 20(1): 41–6, CrossRef.

Hays NP, Roberts SB. The anorexia of aging in humans. Physiol Behav. 2006; 88(3): 257–66, CrossRef.

Murray E, Rudebeck P. The drive to strive: Goal generation based on current needs. Front Neurosci. 2013; 7: 112, CrossRef.

Laugerette F. CD36 involvement in orosensory detection of dietary lipids, spontaneous fat preference, and digestive secretions. J Clin Invest. 2005; 115(11): 3177–84, CrossRef.

Gilbertson TA. Gustatory mechanisms for the detection of fat. Curr Opin Neurobiol. 1998; 8(4): 447–52, CrossRef.

Morrison CD, Berthoud HR. Neurobiology of nutrition and obesity. Nutr Rev. 2008; 65(12): 517–34, CrossRef.

Stern JH, Rutkowski JM, Scherer PE. Adiponectin, leptin, and fatty acids in the maintenance of metabolic homeostasis through adipose tissue crosstalk. Cell Metab. 2016; 23(5): 770–84, CrossRef.

Laeger T, Henagan TM, Albarado DC, Redman LM, Bray GA, Noland RC, et al. FGF21 is an endocrine signal of protein restriction. J Clin Invest. 2014; 124(9): 3913–22, CrossRef.

Berthoud HR, Morrison C. The brain, appetite, and obesity. Annu Rev Psychol. 2008; 59(1): 55–92, CrossRef.

Harris RBS, Kasser TR, Martin RJ. Dynamics of recovery of body composition after overfeeding, food restriction or starvation of mature female rats. J Nutr. 1986; 116(12): 2536–46, CrossRef.

Dent R, McPherson R, Harper ME. Factors affecting weight loss variability in obesity. Metabolism. 2020; 113: 154388, CrossRef.

Hopkins M, Blundell JE. Energy balance, body composition, sedentariness and appetite regulation: Pathways to obesity. Clin Sci. 2016; 130(18): 1615–28, CrossRef.

Martin CK, Johnson WD, Myers CA, Apolzan JW, Earnest CP, Thomas DM, et al. Effect of different doses of supervised exercise on food intake, metabolism, and non-exercise physical activity: The E-MECHANIC randomized controlled trial. Am J Clin Nutr. 2019; 110(3): 583–92, CrossRef.

Foright RM, Presby DM, Sherk VD, Kahn D, Checkley LA, Giles ED, et al. Is regular exercise an effective strategy for weight loss maintenance? Physiol Behav. 2018; 188: 86–93, CrossRef.

Ostendorf DM, Caldwell AE, Creasy SA, Pan Z, Lyden K, Bergouignan A, et al. Physical activity energy expenditure and total daily energy expenditure in successful weight loss maintainers. Obesity. 2019; 27(3): 496–504, CrossRef.

Brand MD, Pakay JL, Ocloo A, Kokoszka J, Wallace DC, Brookes PS, et al. The basal proton conductance of mitochondria depends on adenine nucleotide translocase content. Biochem J. 2005; 392 (Pt 2): 353–62, CrossRef.

Christoffersen BØ, Sanchez‐Delgado G, John LM, Ryan DH, Raun K, Ravussin E. Beyond appetite regulation: Targeting energy expenditure, fat oxidation, and lean mass preservation for sustainable weight loss. Obesity. 2022; 30(4): 841–57, CrossRef.

Flier JS, Kahn CR, Roth J. Receptors, antireceptor antibodies and mechanisms of insulin resistance. N Engl J Med. 1979; 300(8): 413–9, CrossRef.

Holland WL, Summers SA. Sphingolipids, insulin resistance, and metabolic disease: New insights from in vivo manipulation of sphingolipid metabolism. Endocr Rev. 2008; 29(4): 381–402, CrossRef.

Shulman GI. Unraveling the cellular mechanism of insulin resistance in humans: New insights from magnetic resonance spectroscopy. Physiology. 2004; 19: 183–90, CrossRef.

DeFronzo RA, Tripathy D. Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care. 2009; 32(Suppl 2): S157–63, CrossRef.

Petersen KF, Dufour S, Savage DB, Bilz S, Solomon G, Yonemitsu S, et al. The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. Proc Natl Acad Sci USA. 2007; 104(31): 12587–94, CrossRef.

Reitman ML, Gavrilova O. A-ZIP/F-1 mice lacking white fat: A model for understanding lipoatrophic diabetes. Int J Obes Relat Metab Disord. 2000; 24(Suppl 4): S11–14, CrossRef.

Muoio DM. Metabolic inflexibility: When mitochondrial indecision leads to metabolic gridlock. Cell. 2014; 159(6): 1253–62, CrossRef.

Wadden TA, Butryn ML, Byrne KJ. Efficacy of lifestyle modification for long-term weight control. Obes Res. 2004; 12(Suppl): 151S–62S, CrossRef.

Frayn K. Adipose tissue as a buffer for daily lipid flux. Diabetologia. 2002; 45(9): 1201–10, CrossRef.

Scherer PE. Adipose tissue. Diabetes. 2006; 55(6): 1537–45, CrossRef.

Rosen ED, Spiegelman BM. Molecular regulation of adipogenesis. Annu Rev Cell Dev Biol. 2000; 16(1): 145–71, CrossRef.

Parimisetty A, Dorsemans AC, Awada R, Ravanan P, Diotel N, Lefebvre d’Hellencourt C. Secret talk between adipose tissue and central nervous system via secreted factors—An emerging frontier in the neurodegenerative research. J Neuroinflammation. 2016; 13(1): 67, CrossRef.

Lago F, Gómez R, Gómez-Reino JJ, Dieguez C, Gualillo O. Adipokines as novel modulators of lipid metabolism. Trends Biochem Sci. 2009; 34(10): 500–10, CrossRef.

Andrade-Oliveira V, Câmara NOS, Moraes-Vieira PM. Adipokines as drug targets in diabetes and underlying disturbances. J Diabetes Res. 2015; 2015: 81612, CrossRef.

Deng Y, Scherer PE. Adipokines as novel biomarkers and regulators of the metabolic syndrome. Ann NY Acad Sci. 2010; 1212(1): E1–19, CrossRef.

Luo L, Liu M. Adipose tissue in control of metabolism. J Endocrinol. 2016; 231(3): R77–99, CrossRef.

Laviola L, Perrini S, Cignarelli A, Natalicchio A, Leonardini A, De Stefano F, et al. Insulin signaling in human visceral and subcutaneous adipose tissue in vivo. Diabetes. 2006; 55(4): 952–61, CrossRef.

Berry DC, Stenesen D, Zeve D, Graff JM. The developmental origins of adipose tissue. Development. 2013; 140(19): 3939–49, CrossRef.

Chau YY, Bandiera R, Serrels A, Martínez-Estrada OM, Qing W, Lee M, et al. Visceral and subcutaneous fat have different origins and evidence supports a mesothelial source. Nat Cell Biol. 2014; 16(4): 367–75, CrossRef.

Fabbrini E, Tamboli RA, Magkos F, Marks–Shulman PA, Eckhauser AW, Richards WO, et al. Surgical removal of omental fat does not improve insulin sensitivity and cardiovascular risk factors in obese adults. Gastroenterology. 2010; 139(2): 448–55, CrossRef.

Cannon B, Nedergaard J. Brown adipose tissue: Function and physiological significance. Physiol Rev. 2004; 84(1): 277–359, CrossRef.

Wu J, Boström P, Sparks LM, Ye L, Choi JH, Giang AH, et al. Beige adipocytes are a distinct type of thermogenic fat cell in mouse and human. Cell. 2012; 150(2): 366–76, CrossRef.

Jespersen NZ, Larsen TJ, Peijs L, Daugaard S, Homøe P, Loft A, et al. A classical brown adipose tissue mRNA signature partly overlaps with brite in the supraclavicular region of adult humans. Cell Metab. 2013; 17(5): 798–805, CrossRef.

Harms M, Seale P. Brown and beige fat: Development, function and therapeutic potential. Nat Med. 2013; 19(10): 1252–63, CrossRef.

Galitzky J, Carpéné C, Bousquet-Mélou A, Berlan M, Lafontan M. Differential activation of β1-, β2- and β3-adrenoceptors by catecholamines in white and brown adipocytes. Fundam Clin Pharmacol. 1995; 9(4): 324–31, CrossRef.

Weiner J, Kranz M, Klöting N, Kunath A, Steinhoff K, Rijntjes E, et al. Thyroid hormone status defines brown adipose tissue activity and browning of white adipose tissues in mice. Sci Rep. 2016; 6(1): 38124, CrossRef.

Fishman RB, Dark J. Sensory innervation of white adipose tissue. Am J Physiol. 1987; 253(6 Pt 2): R942–4, CrossRef.

Boström P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC, et al. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012; 481(7382): 463–8, CrossRef.

Meiliana A, Dewi NM, Wijaya A. Current progress in adipose tissue biology: Implications in obesity and its comorbidities. Indones Biomed J. 2020; 12(2): 85–101, CrossRef.

Dodd GT, Decherf S, Loh K, Simonds SE, Wiede F, Balland E, et al. Leptin and insulin act on POMC neurons to promote the browning of white fat. Cell. 2015; 160(1–2): 88–104, CrossRef.

Ruan HB, Dietrich MO, Liu ZW, Zimmer MR, Li MD, Singh JP, et al. O-GlcNAc transferase enables AgRP neurons to suppress browning of white fat. Cell. 2014; 159(2): 306–17, CrossRef.

Hu J, Christian M. Hormonal factors in the control of the browning of white adipose tissue. Horm Mol Biol Clin Investig. 2017; 31(1): 1–13, CrossRef.

Summermatter S, Shui G, Maag D, Santos G, Wenk MR, Handschin C. PGC-1α improves glucose homeostasis in skeletal muscle in an activity-dependent manner. Diabetes. 2013; 62(1): 85–95, CrossRef.

Zhang Y, Xie Y, Berglund ED, Coate KC, He TT, Katafuchi T, et al. The starvation hormone, fibroblast growth factor-21, extends lifespan in mice. eLife. 2012; 1: e00065, CrossRef.

Hondares E, Iglesias R, Giralt A, Gonzalez FJ, Giralt M, Mampel T, et al. Thermogenic activation induces FGF21 expression and release in brown adipose tissue. J Biol Chem. 2011; 286(15): 12983–90, CrossRef.

Zhang X, Zhang QX, Wang X, Zhang L, Qu W, Bao B, et al. Dietary luteolin activates browning and thermogenesis in mice through an AMPK/PGC1α pathway-mediated mechanism. Int J Obes. 2016; 40(12): 1841–9, CrossRef.

Qian SW, Tang Y, Li X, Liu Y, Zhang YY, Huang HY, et al. BMP4-mediated brown fat-like changes in white adipose tissue alter glucose and energy homeostasis. Proc Natl Acad Sci USA. 2013; 110(9): E798–807, CrossRef.

Nguyen KD, Qiu Y, Cui X, Goh YPS, Mwangi J, David T, et al. Alternatively activated macrophages produce catecholamines to sustain adaptive thermogenesis. Nature. 2011; 480(7375): 104–8, CrossRef.

Kuji I, Imabayashi E, Minagawa A, Matsuda H, Miyauchi T. Brown adipose tissue demonstrating intense FDG uptake in a patient with mediastinal pheochromocytoma. Ann Nucl Med. 2008; 22(3): 231–5, CrossRef.

Iyer RB, Guo CC, Perrier N. Adrenal pheochromocytoma with surrounding brown fat stimulation. Am J Roentgenol. 2009; 192(1): 300–1, CrossRef.

Baskaran P, Krishnan V, Ren J, Thyagarajan B. Capsaicin induces browning of white adipose tissue and counters obesity by activating TRPV1 channel-dependent mechanisms. Br J Pharmacol. 2016; 173(15): 2369–89, CrossRef.

Singhal V, Maffazioli GD, Ackerman KE, Lee H, Elia EF, Woolley R, et al. Correction: Effect of chronic athletic activity on brown fat in young women. PLoS One. 2016; 11(8): e0160129, CrossRef.

Pan WW, Myers MG. Leptin and the maintenance of elevated body weight. Nat Rev Neurosci. 2018; 19(2): 95–105, CrossRef.

Münzberg H, Morrison CD. Structure, production and signaling of leptin. Metabolism. 2015; 64(1): 13–23, CrossRef.

Friedman J. 20 years of leptin: Leptin at 20: An overview. J Endocrinol. 2014; 223(1): T1–8, CrossRef.

Labbé SM, Caron A, Lanfray D, Monge-Rofarello B, Bartness TJ, Richard D. Hypothalamic control of brown adipose tissue thermogenesis. Front Syst Neurosci. 2015; 9: 150, CrossRef.

Münzberg H, Qualls-Creekmore E, Berthoud HR, Morrison CD, Yu S. Neural control of energy expenditure. Handb Exp Pharmacol. 2016; 233: 173–94, CrossRef.

Caron A, Richard D. Neuronal systems and circuits involved in the control of food intake and adaptive thermogenesis. Ann NY Acad Sci. 2017; 1391(1): 35–53, CrossRef.

Contreras C, González-García I, Martínez-Sánchez N, Seoane-Collazo P, Jacas J, Morgan DA, et al. Central ceramide-induced hypothalamic lipotoxicity and ER stress regulate energy balance. Cell Rep. 2014; 9(1): 366–77, CrossRef.

Allison MB, Myers MG. 20 years of leptin: Connecting leptin signaling to biological function. J Endocrinol. 2014; 223(1): T25–35, CrossRef.

Rizzo M, Rizvi AA, Sudar E, Soskic S, Obradovic M, Montalto G, et al. A review of the cardiovascular and anti-atherogenic effects of ghrelin. Curr Pharm Des. 2013; 19(27): 4953–63, CrossRef.

Nagaya N, Uematsu M, Kojima M, Ikeda Y, Yoshihara F, Shimizu W, et al. Chronic administration of ghrelin improves left ventricular dysfunction and attenuates development of cardiac cachexia in rats with heart failure. Circulation. 2001; 104(12): 1430–5, CrossRef.

Okumura H, Nagaya N, Enomoto M, Nakagawa E, Oya H, Kangawa K. Vasodilatory effect of ghrelin, an endogenous peptide from the stomach. J Cardiovasc Pharmacol. 2002; 39(6): 779–83, CrossRef.

Kojima M, Kangawa K. Ghrelin: Structure and function. Physiol Rev. 2005; 85(2): 495–522, CrossRef.

Tschöp M, Wawarta R, Riepl RL, Friedrich S, Bidlingmaier M, Landgraf R, et al. Post-prandial decrease of circulating human ghrelin levels. J Endocrinol Invest. 2001; 24(6): RC19–21, CrossRef.

Müller TD, Nogueiras R, Andermann ML, Andrews ZB, Anker SD, Argente J, et al. Ghrelin. Mol Metab. 2015; 4(6): 437–60, CrossRef.

Hay DL, Chen S, Lutz TA, Parkes DG, Roth JD. Amylin: Pharmacology, physiology, and clinical potential. Pharmacol Rev. 2015; 67(3): 564–600, CrossRef.

Jorsal T, Rungby J, Knop FK, Vilsbøll T. GLP-1 and amylin in the treatment of obesity. Curr Diab Rep. 2016; 16(1): 1, CrossRef.

Boyle CN, Lutz TA, Le Foll C. Amylin – Its role in the homeostatic and hedonic control of eating and recent developments of amylin analogs to treat obesity. Mol Metab. 2018; 8: 203–10, CrossRef.

Betz MJ, Enerbäck S. Targeting thermogenesis in brown fat and muscle to treat obesity and metabolic disease. Nat Rev Endocrinol. 2018; 14(2): 77–87, CrossRef.

Villarroya F, Cereijo R, Villarroya J, Giralt M. Brown adipose tissue as a secretory organ. Nat Rev Endocrinol. 2017; 13(1): 26–35, CrossRef.

Lehnig AC, Stanford KI. Exercise-induced adaptations to white and brown adipose tissue. J Exp Biol. 2018; 221(Suppl 1): jeb161570, CrossRef.

Mendez-Gutierrez A, Osuna-Prieto FJ, Aguilera CM, Ruiz JR, Sanchez-Delgado G. Endocrine mechanisms connecting exercise to brown adipose tissue metabolism: A human perspective. Curr Diab Rep. 2020; 20(9): 40, CrossRef.

Volpe M. Natriuretic peptides and cardio-renal disease. Int J Cardiol. 2014; 176(3): 630–9, CrossRef.

Lafontan M, Moro C, Berlan M, Crampes F, Sengenes C, Galitzky J. Control of lipolysis by natriuretic peptides and cyclic GMP. Trends Endocrinol Metab. 2008; 19(4): 130–7, CrossRef.

Engeli S, Birkenfeld AL, Badin PM, Bourlier V, Louche K, Viguerie N, et al. Natriuretic peptides enhance the oxidative capacity of human skeletal muscle. J Clin Invest. 2012; 122(12): 4675–9, CrossRef.

Ohba H, Takada H, Musha H, Nagashima J, Mori N, Awaya T, et al. Effects of prolonged strenuous exercise on plasma levels of atrial natriuretic peptide and brain natriuretic peptide in healthy men. Am Heart J. 2001; 141(5): 751–8, CrossRef.

Aengevaeren VL, Hopman MTE, Thijssen DHJ, van Kimmenade RR, de Boer MJ, Eijsvogels TMH. Endurance exercise-induced changes in BNP concentrations in cardiovascular patients versus healthy controls. Int J Cardiol. 2017; 227: 430–5, CrossRef.

Pathak V, Aris R, Jensen BC, Huang W, Ford HJ. Effect of 6-min walk test on pro-BNP levels in patients with pulmonary arterial hypertension. Lung. 2018; 196(3): 315–9, CrossRef.

de Oliveira M, Mathias LS, Rodrigues BM, Mariani BG, Graceli JB, De Sibio MT, et al. The roles of triiodothyronine and irisin in improving the lipid profile and directing the browning of human adipose subcutaneous cells. Mol Cell Endocrinol. 2020; 506: 110744, CrossRef.

Dünnwald T, Melmer A, Gatterer H, Salzmann K, Ebenbichler C, Burtscher M, et al. Supervised short-term high-intensity training on plasma irisin concentrations in type 2 diabetic patients. Int J Sports Med. 2019; 40(3): 158–64, CrossRef.

Fisher FM, Kleiner S, Douris N, Fox EC, Mepani RJ, Verdeguer F, et al. FGF21 regulates PGC-1α and browning of white adipose tissues in adaptive thermogenesis. Genes Dev. 2012; 26(3): 271–81, CrossRef.

Soundarrajan M, Deng J, Kwasny M, Rubert NC, Nelson PC, El-Seoud DA, et al. Activated brown adipose tissue and its relationship to adiposity and metabolic markers: An exploratory study. Adipocyte. 2020; 9(1): 87–95, CrossRef.

Subbotina E, Sierra A, Zhu Z, Gao Z, Koganti SRK, Reyes S, et al. Musclin is an activity-stimulated myokine that enhances physical endurance. Proc Natl Acad Sci USA. 2015; 112(52): 16042–7, CrossRef.

Jeremic N, Chaturvedi P, Tyagi SC. Browning of white fat: Novel insight into factors, mechanisms, and therapeutics. J Cell Physiol. 2017; 232(1): 61–8, CrossRef.

Campderrós L, Moure R, Cairó M, Gavaldà-Navarro A, Quesada-López T, Cereijo R, et al. Brown adipocytes secrete GDF15 in response to thermogenic activation. Obesity. 2019; 27(10): 1606–16, CrossRef.

Galliera E, Lombardi G, Marazzi MG, Grasso D, Vianello E, Pozzoni R, et al. Acute exercise in elite rugby players increases the circulating level of the cardiovascular biomarker GDF-15. Scand J Clin Lab Invest. 2014; 74(6): 492–9, CrossRef.

Kleinert M, Clemmensen C, Sjøberg KA, Carl CS, Jeppesen JF, Wojtaszewski JFP, et al. Exercise increases circulating GDF15 in humans. Mol Metab. 2018; 9: 187–91, CrossRef.

McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature. 1997; 387(6628): 83–90, CrossRef.

Shan T, Liang X, Bi P, Kuang S. Myostatin knockout drives browning of white adipose tissue through activating the AMPK-PGC1α-Fndc5 pathway in muscle. FASEB J Off Publ Fed Am Soc Exp Biol. 2013; 27(5): 1981–9, CrossRef.

Kabak B, Belviranli M, Okudan N. Irisin and myostatin responses to acute high-intensity interval exercise in humans. Horm Mol Biol Clin Investig. 2018; 35(3): 20180008, CrossRef.

Bagheri R, Moghadam BH, Church DD, Tinsley GM, Eskandari M, Moghadam BH, et al. The effects of concurrent training order on body composition and serum concentrations of follistatin, myostatin and GDF11 in sarcopenic elderly men. Exp Gerontol. 2020; 133: 110869, CrossRef.

Singh R, Braga M, Reddy ST, Lee SJ, Parveen M, Grijalva V, et al. Follistatin targets distinct pathways to promote brown adipocyte characteristics in brown and white adipose tissues. Endocrinology. 2017; 158(5): 1217–30, CrossRef.

Li JX, Cummins CL. Getting the skinny on follistatin and fat. Endocrinology. 2017; 158(5): 1109–12, CrossRef.

Stanford KI, Goodyear LJ. Exercise regulation of adipose tissue. Adipocyte. 2016; 5(2): 153–62, CrossRef.

Wrann CD, White JP, Salogiannnis J, Laznik-Bogoslavski D, Wu J, Ma D, et al. Exercise induces hippocampal BDNF through a PGC-1α/FNDC5 pathway. Cell Metab. 2013; 18(5): 649–59, CrossRef.

Hung CL, Tseng JW, Chao HH, Hung TM, Wang HS. Effect of acute exercise mode on serum brain-derived neurotrophic factor (BDNF) and task switching performance. J Clin Med. 2018; 7(10): 301, CrossRef.

Simão AP, Mendonça VA, Avelar NCP, da Fonseca SF, Santos JM, de Oliveira ACC, et al. Whole body vibration training on muscle strength and brain-derived neurotrophic factor levels in elderly woman with knee osteoarthritis: A randomized clinical trial study. Front Physiol. 2019; 10: 756, CrossRef.

Marinus N, Hansen D, Feys P, Meesen R, Timmermans A, Spildooren J. The impact of different types of exercise training on peripheral blood brain-derived neurotrophic factor concentrations in older adults: A meta-analysis. Sports Med Auckl NZ. 2019; 49(10): 1529–46, CrossRef.

Devenney KE, Guinan EM, Kelly ÁM, Mota BC, Walsh C, Olde Rikkert M, et al. Acute high-intensity aerobic exercise affects brain-derived neurotrophic factor in mild cognitive impairment: A randomised controlled study. BMJ Open Sport Exerc Med. 2019; 5(1): e000499, CrossRef.

Jürimäe J, Hofmann P, Jürimäe T, Mäestu J, Purge P, Wonisch M, et al. Plasma adiponectin response to sculling exercise at individual anaerobic threshold in college level male rowers. Int J Sports Med. 2006; 27(4): 272–7, CrossRef.

Jürimäe J, Purge P, Jürimäe T. Adiponectin is altered after maximal exercise in highly trained male rowers. Eur J Appl Physiol. 2005; 93(4): 502–5, CrossRef.

Jürimäe J, Purge P, Jürimäe T. Adiponectin and stress hormone responses to maximal sculling after volume-extended training season in elite rowers. Metabolism. 2006; 55(1): 13–9, CrossRef.

Racil G, Ben Ounis O, Hammouda O, Kallel A, Zouhal H, Chamari K, et al. Effects of high vs. moderate exercise intensity during interval training on lipids and adiponectin levels in obese young females. Eur J Appl Physiol. 2013; 113(10): 2531–40, CrossRef.

Ingerslev B, Hansen JS, Hoffmann C, Clemmesen JO, Secher NH, Scheler M, et al. Angiopoietin-like protein 4 is an exercise-induced hepatokine in humans, regulated by glucagon and cAMP. Mol Metab. 2017; 6(10): 1286–95, CrossRef.

Shimomura Y, Honda T, Shiraki M, Murakami T, Sato J, Kobayashi H, et al. Branched-chain amino acid catabolism in exercise and liver disease. J Nutr. 2006; 136(1): 250S–3S, CrossRef.

Roberts LD, Boström P, O’Sullivan JF, Schinzel RT, Lewis GD, Dejam A, et al. β-Aminoisobutyric acid induces browning of white fat and hepatic β-oxidation and is inversely correlated with cardiometabolic risk factors. Cell Metab. 2014; 19(1): 96–108, CrossRef.

Evans M, Cogan KE, Egan B. Metabolism of ketone bodies during exercise and training: Physiological basis for exogenous supplementation. J Physiol. 2017; 595(9): 2857–71, CrossRef.

Margolis LM, O’Fallon KS. Utility of ketone supplementation to enhance physical performance: A systematic review. Adv Nutr. 2020; 11(2): 412–9, CrossRef.

O’Mara AE, Johnson JW, Linderman JD, Brychta RJ, McGehee S, Fletcher LA, et al. Chronic mirabegron treatment increases human brown fat, HDL cholesterol, and insulin sensitivity. J Clin Invest. 2020; 130(5): 2209–19, CrossRef.

Finlin BS, Memetimin H, Zhu B, Confides AL, Vekaria HJ, El Khouli RH, et al. The β3-adrenergic receptor agonist mirabegron improves glucose homeostasis in obese humans. J Clin Invest. 2020; 130(5): 2319–31, CrossRef.

Li S, Li Y, Xiang L, Dong J, Liu M, Xiang G. Sildenafil induces browning of subcutaneous white adipose tissue in overweight adults. Metabolism. 2018; 78: 106–17, CrossRef.

Baskin AS, Linderman JD, Brychta RJ, McGehee S, Anflick-Chames E, Cero C, et al. Regulation of human adipose tissue activation, gallbladder size, and bile acid metabolism by a β3-adrenergic receptor agonist. Diabetes. 2018; 67(10): 2113–25, CrossRef.

Loh RKC, Formosa MF, La Gerche A, Reutens AT, Kingwell BA, Carey AL. Acute metabolic and cardiovascular effects of mirabegron in healthy individuals. Diabetes Obes Metab. 2019; 21(2): 276–84, CrossRef.

Cuevas-Ramos D, Mehta R, Aguilar-Salinas CA. Fibroblast growth factor 21 and browning of white adipose tissue. Front Physiol. 2019; 10: 37, CrossRef.

Drucker DJ, Nauck MA. The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006; 368(9548): 1696–705, CrossRef.

Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013; 17(6): 819–37, CrossRef.

Nogueiras R, Pérez-Tilve D, Veyrat-Durebex C, Morgan DA, Varela L, Haynes WG, et al. Direct control of peripheral lipid deposition by CNS GLP-1 receptor signaling is mediated by the sympathetic nervous system and blunted in diet-induced obesity. J Neurosci. 2009; 29(18): 5916–25, CrossRef.

Müller TD, Finan B, Bloom SR, D’Alessio D, Drucker DJ, Flatt PR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019; 30: 72–130, CrossRef.

Astrup A, Rössner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M, et al. Effects of liraglutide in the treatment of obesity: A randomised, double-blind, placebo-controlled study. Lancet. 2009; 374(9701): 1606–16, CrossRef.

Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018; 27(4): 740–56, CrossRef.

Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, et al. Triple-hormone-receptor agonist retatrutide for obesity — A phase 2 trial. N Engl J Med. 2023; 389(6): 514–26, CrossRef.

Sin N, Meng L, Wang MQ, Wen JJ, Bornmann WG, Crews CM. The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proc Natl Acad Sci USA. 1997; 94(12): 6099–103, CrossRef.

Lijnen HR, Frederix L, Van Hoef B. Fumagillin reduces adipose tissue formation in murine models of nutritionally induced obesity. Obesity. 2010; 18(12): 2241–6, CrossRef.

Datta B, Majumdar A, Datta R, Balusu R. Treatment of cells with the angiogenic inhibitor fumagillin results in increased stability of eukaryotic initiation factor 2-associated glycoprotein, p67, and reduced phosphorylation of extracellular signal-regulated kinases. Biochemistry. 2004; 43(46): 14821–31, CrossRef.

Hughes TE, Kim DD, Marjason J, Proietto J, Whitehead JP, Vath JE. Ascending dose-controlled trial of beloranib, a novel obesity treatment for safety, tolerability, and weight loss in obese women. Obesity. 2013; 21(9): 1782–8, CrossRef.

An J, Wang L, Patnode ML, Ridaura VK, Haldeman JM, Stevens RD, et al. Physiological mechanisms of sustained fumagillin-induced weight loss. JCI Insight. 2018; 3(5): e99453, CrossRef.

DOI: https://doi.org/10.18585/inabj.v16i1.2840

Copyright (c) 2024 The Prodia Education and Research Institute

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.


Indexed by:






The Prodia Education and Research Institute